Canary Bio Appoints Clinical Expert Seungyoung Choi as Head of Department
[Asia Economy Reporter Hyungsoo Park] Canaria Bio has recruited experts to strengthen its research and development and clinical personnel. Canaria Bio announced on the 20th that it has hired Seungyoung Choi as the head of clinical development.
Head Seungyoung Choi earned a master's degree in immunology from Seoul National University and worked as a researcher for two years. He is a clinical expert who gained clinical management experience at global CROs including Parexel and later managed clinical trials as a sponsor at GemVax and HLB.
Canaria Bio CEO Hanik Na said, "Head Seungyoung Choi has directly conducted clinical trials at global CROs for the past 17 years," adding, "As a clinical veteran who managed CROs from the sponsor's perspective, he is the right person to lead the management of the global Phase 3 clinical trial of Oregovomab targeting new ovarian cancer patients."
Hot Picks Today
SpaceX Opens IPO Floodgates... Anthropic and OpenAI Push Valuations into the Trillions
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "From 119 Call to Hospital Transport"... Saving Sudden Cardiac Arrest Patients with AI and Video Calls
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Oregovomab, Canaria Bio's core pipeline undergoing a global Phase 3 clinical trial, showed results in the Phase 2 trial targeting new ovarian cancer patients, with progression-free survival (PFS) extended by 30 months compared to the existing standard treatment, reaching 42 months.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
